Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
RGC
Upturn stock ratingUpturn stock rating

Regencell Bioscience Holdings Ltd (RGC)

Upturn stock ratingUpturn stock rating
$595.1
Last Close (24-hour delay)
Profit since last BUY4615.53%
upturn advisory
Consider higher Upturn Star rating
BUY since 64 days
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

06/13/2025: RGC (1-star) has a low Upturn Star Rating. Not recommended to BUY.

Upturn Star Rating

ratingratingratingratingrating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Analysis of Past Performance

Type Stock
Historic Profit 2041.82%
Avg. Invested days 38
Today’s Advisory Consider higher Upturn Star rating
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 2.0
Stock Returns Performance Upturn Returns Performance 5.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 06/13/2025

Key Highlights

Company Size Mid-Cap Stock
Market Capitalization 7.74B USD
Price to earnings Ratio -
1Y Target Price -
Price to earnings Ratio -
1Y Target Price -
Volume (30-day avg) 73202
Beta 2.62
52 Weeks Range 3.03 - 950.00
Updated Date 06/14/2025
52 Weeks Range 3.03 - 950.00
Updated Date 06/14/2025
Dividends yield (FY) -
Basic EPS (TTM) -0.01

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -

Management Effectiveness

Return on Assets (TTM) -28.11%
Return on Equity (TTM) -43.18%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 195912836
Price to Sales(TTM) -
Enterprise Value 195912836
Price to Sales(TTM) -
Enterprise Value to Revenue -
Enterprise Value to EBITDA -44.58
Shares Outstanding 13012900
Shares Floating 786888
Shares Outstanding 13012900
Shares Floating 786888
Percent Insiders 93.84
Percent Institutions 0.07

Analyst Ratings

Rating -
Target Price -
Buy -
Strong Buy -
Buy -
Strong Buy -
Hold -
Sell -
Strong Sell -
Strong Sell -

ai summary icon Upturn AI SWOT

Regencell Bioscience Holdings Ltd

stock logo

Company Overview

overview logo History and Background

Regencell Bioscience Holdings Ltd, founded in 2019, focuses on the research, development, and commercialization of Traditional Chinese Medicine (TCM) for the treatment of diseases such as ADHD and other neurocognitive disorders. It has primarily focused on research and development.

business area logo Core Business Areas

  • Research and Development: Focuses on TCM formulas for neurocognitive disorders, including ADHD. Conducts clinical trials and studies to validate efficacy and safety.
  • Potential Commercialization: Aims to commercialize TCM formulas through licensing, partnerships, or direct sales if clinical trials are successful and regulatory approval is obtained.

leadership logo Leadership and Structure

The leadership team is relatively small and centered around the CEO. The organizational structure appears to be lean, reflecting the early-stage nature of the company.

Top Products and Market Share

overview logo Key Offerings

  • RGC-COV19: A TCM formula under development for treating COVID-19. Clinical trials have been conducted, but commercialization is uncertain. Market share is currently zero as it's not yet approved for sale. Competitors include pharmaceutical companies with approved COVID-19 treatments (e.g., Pfizer, Merck).
  • ADHD Treatment (TCM Formula): A TCM formula under development for ADHD treatment. Currently in research and development phase. Market share is currently zero. Competitors include pharmaceutical companies with approved ADHD medications (e.g., Novartis, Eli Lilly).

Market Dynamics

industry overview logo Industry Overview

The industry involves the development and commercialization of pharmaceutical products and TCM. The pharmaceutical market is highly competitive and regulated. The TCM market is growing but faces challenges related to scientific validation and regulatory acceptance.

Positioning

Regencell is a small player in the pharmaceutical and TCM markets. Its competitive advantage, if any, relies on the potential efficacy and acceptance of its TCM formulas.

Total Addressable Market (TAM)

The global ADHD therapeutics market size was valued at USD 13.7 billion in 2022 and is expected to reach USD 25.0 billion by 2032. Regencell's position depends on successful trials and commercialization.

Upturn SWOT Analysis

Strengths

  • Focus on TCM
  • Novel TCM formula development
  • Potential for alternative treatment options

Weaknesses

  • Early-stage company
  • Limited financial resources
  • Reliance on successful clinical trials
  • Dependence on single or small number of treatments

Opportunities

  • Growing interest in TCM
  • Potential partnerships with pharmaceutical companies
  • Expansion into new markets
  • Evolving regulatory landscape for TCM

Threats

  • Regulatory hurdles
  • Competition from established pharmaceutical companies
  • Clinical trial failures
  • Lack of market acceptance of TCM
  • Funding risks

Competitors and Market Share

competitor logo Key Competitors

  • LLY
  • NVS
  • PFE
  • MRK

Competitive Landscape

Regencell faces significant disadvantages compared to established pharmaceutical companies. Its success hinges on differentiating its TCM formulas and gaining market acceptance.

Major Acquisitions

Growth Trajectory and Initiatives

Historical Growth: Limited historical growth due to being an early-stage R&D company.

Future Projections: Future growth is entirely dependent on successful clinical trials, regulatory approvals, and commercialization of its TCM formulas. Analyst estimates are speculative.

Recent Initiatives: Recent initiatives focus on ongoing clinical trials for RGC-COV19 and the ADHD treatment.

Summary

Regencell Bioscience Holdings Ltd is a very early-stage pharmaceutical company with a high-risk, high-reward profile. Its success depends on the successful development and commercialization of its TCM formulas, which faces regulatory and market acceptance hurdles. The company has limited financial resources and significant competition from established pharmaceutical companies. Investment in Regencell is highly speculative.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company Filings
  • Industry Reports
  • Analyst Reports
  • Company Press Releases

Disclaimers:

The information provided is for informational purposes only and should not be considered financial advice. Investment decisions should be based on thorough research and consultation with a qualified financial advisor. Market data is indicative and subject to change.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Regencell Bioscience Holdings Ltd

Exchange NASDAQ
Headquaters -
IPO Launch date 2021-07-16
Founder, Chairman & CEO Mr. Yat-Gai Au
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
Full time employees 12
Full time employees 12

Regencell Bioscience Holdings Limited operates as a Traditional Chinese medicine (TCM) bioscience company in Hong Kong. The company focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily for attention deficit hyperactivity disorder and autism spectrum disorder. Regencell Bioscience Holdings Limited was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.